Search
vilazodone (Viibryd)
Indications:
- major depression (FDA-approved Jan 2011)
Contraindications:
- vilazodone & MAO inhibitors should not be used together or within 14 days of each other
Pregnancy category: C
Dosage:
- start 10 mg QD with food
- after 7 days, increase to 20 mg QD
- after 14 days, increase to 40 mg QD, dose with food
- taper if discontinuing [2]
Tabs: 10, 20, 40 mg
Pharmacokinetics:
- metabolized by CYP3A4
- inhibits CYP2C8
- protein-binding 96-99%
Adverse effects:
- diarrhea (28%), nausea (23%), vomiting (5%)
- dizziness (9%)
- xerostomia (6%)
- xerophthalmia (5%) [2]
- insomnia
- may cause new or worsening cataracts [2]
- minimal or no sexual dysfunction
- minimal or no weight gain
- also see SSRI
Drug interactions:
- inhibitors of CYP3A4 may increase vilazodone levels
- vilazodone could potentially increase levels of drugs metabolized by CYP2C8 [2]
Laboratory:
- vilazodone in urine
Mechanism of action:
- combined selective serotonin reuptake inhibitor & serotonin 1A receptor partial agonist
Interactions
drug adverse effects of SSRIs
Related
serotonin [5HT]-1A receptor; 5-hydroxytryptamine receptor 1A; 5-HT-1A; 5-HT1A; serotonin receptor 1A; G-21 (HTR1A, ADRB2RL1, ADRBRL1)
serotonin; 5-hydroxytryptamine
General
selective serotonin reuptake inhibitor (SSRI)
References
- FDA NEWS RELEASE, Jan. 21, 2011
FDA approves Viibryd to treat major depressive disorder
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm240642.htm
- Prescriber's Letter 18(7): 2011
New Drug: Viibryd (Vilazodone)
Detail-Document#: 270706
(subscription needed) http://www.prescribersletter.com